Esperion Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$28.9M
Doctors Paid
41,623
Transactions
197,077
2024 Total
$1.7M
Payment Breakdown by Category
Research$16.2M (56.1%)
Food & Beverage$4.0M (13.9%)
Travel$803,838 (2.8%)
Consulting$130,736 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16.2M | 24,297 | 56.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7.7M | 3,728 | 26.7% |
| Food and Beverage | $4.0M | 166,651 | 13.9% |
| Travel and Lodging | $803,838 | 1,947 | 2.8% |
| Consulting Fee | $130,736 | 53 | 0.5% |
| Education | $17,697 | 394 | 0.1% |
| Honoraria | $16,400 | 7 | 0.1% |
Payments by Type
Research
$16.2M
24,297 transactions
General
$12.7M
172,780 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT | $15.6M | 1 | 24,271 |
| Exploring the anti-inflammatory characteristics of bempedoic acid (ETC-1002) retrospectively in a study population with elevated hs-CRP (> 2.0) at the baseline measurement | $264,000 | 0 | 3 |
| Predicting 10-year risk of cardiovascular events in Baylor Scott & White Cardiology Patients with Established Cardiovascular Disease | $143,000 | 0 | 2 |
| A Phase 1, Open-label, single-dose study to evaluate the pharmacokinetics of bempedoic acid in health subjects with normal renal function and subjects with ends-stage renal disease receiving hemodialysis | $107,465 | 0 | 15 |
| Houston Methodist Big Data Lipid Management Initiative | $32,000 | 0 | 1 |
| Quantify the biomarker GDF-51 | $27,720 | 0 | 1 |
| Describe the impact of utilization management on patient access to Bempedoic Acid | $220.00 | 0 | 2 |
| A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing | $110.00 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| John Isaac, M.d, M.D | Interventional Cardiology | Houston, TX | $355,569 | $0 |
| William Cromwell, M.d, M.D | Family Medicine | Raleigh, NC | $328,716 | $0 |
| Matthew Budoff, M.d, M.D | Cardiovascular Disease | Torrance, CA | $302,517 | $0 |
| Dr. Payal Kohli, M.d, M.D | Internal Medicine | Aurora, CO | $295,971 | $0 |
| Denzil Moraes, M.d, M.D | Cardiovascular Disease | Baton Rouge, LA | $200,078 | $0 |
| Jaime Burkle, Md, MD | Nuclear Cardiology | Gainesville, GA | $177,455 | $0 |
| Dr. Jonathan Lown, Md, MD | Sleep Medicine | Commack, NY | $171,447 | $0 |
| Dr. Yili Huang, D.o, D.O | Adult Congenital Heart Disease | Elmhurst, NY | $142,104 | $0 |
| Dean Karalis, Md, MD | Cardiovascular Disease | Philadelphia, PA | $137,032 | $0 |
| Brett Nowlan, Md, MD | Cardiovascular Disease | Bloomfield, CT | $125,726 | $0 |
| Eliot Brinton, Md, MD | Endocrinology, Diabetes & Metabolism | Salt Lake City, UT | $116,295 | $0 |
| Dr. Norman Lepor, M.d, M.D | Specialist | Beverly Hills, CA | $107,309 | $0 |
| Narendra Singh, Md, MD | Cardiovascular Disease | Johns Creek, GA | $107,256 | $0 |
| Alan Brown, Md, MD | Cardiovascular Disease | Naperville, IL | $106,668 | $0 |
| Dr. Khalid Sheikh, Md, MD | Cardiovascular Disease | Melbourne, FL | $104,900 | $0 |
| John Gerald Canto, Md, MD | Cardiovascular Disease | Lakeland, FL | $100,239 | $0 |
| David Perloff, Md, MD | Cardiovascular Disease | Fort Lauderdale, FL | $98,101 | $0 |
| Dr. Henry Siu, M.d, M.D | Interventional Cardiology | New York, NY | $97,780 | $0 |
| Dr. Robert Busch, M.d, M.D | Endocrinology, Diabetes & Metabolism | Albany, NY | $91,306 | $0 |
| Dr. Allen Taylor, M.d, M.D | Cardiovascular Disease | N Bethesda, MD | $85,105 | $0 |
| Dr. Ziad Abbud, Md, MD | Specialist | Neptune, NJ | $82,414 | $0 |
| Arindam Banerjee, M. D, M. D | Internal Medicine | Conroe, TX | $79,270 | $0 |
| Kathleen Drinan, Do, DO | Cardiovascular Disease | Orland Park, IL | $76,000 | $0 |
| Eric Stocker, Md, MD | Cardiovascular Disease | San Antonio, TX | $75,830 | $0 |
| Dr. Dharmesh Patel, Md, MD | Cardiovascular Disease | Southaven, MS | $75,641 | $0 |
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. has made $28.9M in payments to 41,623 healthcare providers, recorded across 197,077 transactions in the CMS Open Payments database. In 2024, the company paid $1.7M. The top product by payment volume is NEXLETOL ($19.0M).
Payments were distributed across 214 medical specialties. The top specialty by payment amount is Cardiovascular Disease ($4.5M to 4,720 doctors).
Payment categories include: Food & Beverage ($4.0M), Consulting ($130,736), Research ($16.2M), Travel & Lodging ($803,838).
Esperion Therapeutics, Inc. is associated with 2 products in the CMS Open Payments database.